Bristol-Myers Squibb Co vs Hasbro, Inc. — how do they compare? Bristol-Myers Squibb Co trades at $63.9 (market cap $129.94B), while Hasbro, Inc. trades at $96.13 (market cap $13.69B). The key difference: Bristol-Myers Squibb Co is far larger — about 9.5× Hasbro, Inc.'s market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | HAS | |
|---|---|---|
Market Cap | $129.94B | $13.69B |
Sector | Health | Consumer Cyclical |
52-Week High | $65.89 | $105.88 |
52-Week Low | $42.60 | $70.95 |
Enterprise Value | $163.92B | $15.88B |
Dividend Yield | 3.96% | 2.89% |
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.
Hasbro (HAS) trades at $94.49, up 1.04% today, with strong technical and fundamental momentum. The stock exhibits a bullish trend, supported by consecutive earnings beats in Q4 2025, Q1 2026, and Q2 2026. Recent news highlights growth in adult-focused segments like Magic: The Gathering, with Q2 2026 revenue up 16% year-over-year. Valuation metrics show a P/E of 17.27 and P/S of 2.77, while analyst consensus is bullish with a $104.90 price target.
The outlook for Hasbro is positive, driven by IP strength and digital gaming growth, but risks include margin pressures from tariffs and high debt levels. Institutional buying and a 51.52% buy rating from analysts support upside potential, though investors should monitor execution risks and macroeconomic headwinds. The stock's current price is within 5% of its 52-week high, indicating strong near-term momentum.
Trailing returns across standard periods
Latest headlines on both assets
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →